BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $36,820,000 | -2.4% | 457,396 | +2.2% | 2.05% | -11.7% |
| Q1 2021 | $37,743,000 | +7.6% | 447,512 | +2.3% | 2.32% | -0.4% |
| Q4 2020 | $35,085,000 | +1.1% | 437,245 | +1.3% | 2.33% | -10.4% |
| Q3 2020 | $34,709,000 | -4.9% | 431,591 | +1.8% | 2.60% | -15.7% |
| Q2 2020 | $36,501,000 | +7.6% | 423,938 | +1.4% | 3.09% | -14.9% |
| Q1 2020 | $33,936,000 | +2.8% | 417,987 | +5.8% | 3.63% | +24.0% |
| Q4 2019 | $33,027,000 | -4.5% | 394,961 | -0.1% | 2.92% | -8.6% |
| Q3 2019 | $34,583,000 | -1.8% | 395,366 | -8.1% | 3.20% | +0.9% |
| Q2 2019 | $35,219,000 | -2.1% | 430,021 | -2.8% | 3.17% | -6.2% |
| Q1 2019 | $35,972,000 | +21.5% | 442,408 | -1.7% | 3.38% | +12.7% |
| Q4 2018 | $29,615,000 | -17.6% | 449,935 | -3.5% | 3.00% | -1.4% |
| Q3 2018 | $35,958,000 | +3.8% | 466,440 | -0.5% | 3.04% | -1.3% |
| Q2 2018 | $34,628,000 | +211.0% | 468,964 | +176.7% | 3.08% | -1.4% |
| Q3 2013 | $11,135,000 | -6.1% | 169,502 | -1.0% | 3.12% | -4.9% |
| Q2 2013 | $11,855,000 | – | 171,137 | – | 3.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |